249 OPERAM: cluster randomised controlled trial 34. Drenth-van Maanen AC, Spee J, van Hensbergen L, Jansen PA, Egberts TC, van Marum RJ. Structured history taking of medication use reveals iatrogenic harm due to discrepancies in medication histories in hospital and pharmacy records. J Am Geriatr Soc. 2011;59:1976–7. 35. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherencemeasure for hypertension control. JClinHypertens Greenwich. 2008;10:348–54. 36. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15:59–66. 37. Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: Final response. J Clin Epidemiol. 2011;64:258–63. 38. Thevelin S, Spinewine A, Beuscart JB, et al. Development of a Standardized Chart ReviewMethod to Identify Drug-Related Hospital Admissions in Older People. Br J Clin Pharmacol. 2018;84:2600-14. 39. Arnold BF, Ercumen A. Negative Control Outcomes: A Tool to Detect Bias in Randomized Trials. JAMA. 2016;316:2597–8. 40. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–108. 41. Beuscart J-B, Knol W, Cullinan S, et al. International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy. BMC Med. 2018;16:21. 42. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J. 1965;14:61–5. 43. Anrys P, Petit A-E, Thevelin S, Sallevelt B, Drenth C, Soiza RL, et al. An International Consensus List of Potentially Clinically Significant Drug-Drug Interactions in Older People. J Am Med Dir Assoc. 2021;S1525-8610:00315-7. 44. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. Ann Fam Med. 2012;10:142–51. 45. Tal S, Guller V, Shavit Y, Stern F, Malnick S. Mortality predictors in hospitalized elderly patients. QJM. 2011;104:933–8. 46. Smeeth L, Ng ES. Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community. Control Clin Trials. 2002;23:409–21. 47. Hemming K, Marsh J. A Menu-Driven Facility for Sample-Size Calculations in Cluster Randomized Controlled Trials. Stata J. 2013;13:114–35. 48. Stephen Senn: “Delta Force: To what extent is clinical relevance relevant?” (Guest Post) | Error Statistics Philosophy [Internet]. 2014 [cited 2021 May 3]. Available from: https:// errorstatistics.com/2014/03/17/stephen-senn-on-how-to-interpret-discrepanciesagainst-which-a-test-has-high-power-guest-post/ 49. Therneau TM, Lumley T, Elizabeth A, Cynthia C. survival: Survival Analysis [Internet]. 2020 [cited 2021 Feb 14]. Available from: https://CRAN.R-project.org/package=survival 50. Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics Based on Weighted Residuals. Biometrika. 1994;81:515–26. 51. Yang S, Starks MA, Hernandez AF, et al. Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. Contemp Clin Trials. 2020;88:105775. 52. Hernán MA, Robins JM. Per-Protocol Analyses of Pragmatic Trials. N Engl J Med. 2017;377:1391–8. 53. R Core Team. R: A language and environment for statistical computing. R Found Stat Comput Vienna Austria. 2013. 3
RkJQdWJsaXNoZXIy MTk4NDMw